secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001193125-23-002504
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02, 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics ends Janssen deal, cuts workforce to 220, discontinues four NK programs
--------------------------------------------------------------------------------

- Janssen collaboration terminated effective April 3, 2023; all activities wound down in Q1 2023.
- Workforce reduced to ~220 employees; expects $15M severance charges in Q1 2023.
- Discontinues FT516, FT596, FT538, FT536 NK programs; focuses on second-gen CD19 CAR NK, FT576, FT819, FT825/ONO-8250.
- CTO Mark Plavsic to depart March 6, 2023; receives 9 months base salary and equity acceleration.
- Unrestricted cash, equivalents, and receivables ~$475M at year-end 2022; cash runway extended through 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312523002504/0001193125-23-002504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312523002504/d418503d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-002504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer